Navigation Links
Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
Date:6/17/2009

armaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the funding arrangement, credit facility and other agreements with Deerfield, the expected funding and related actions thereunder; the anticipated completion of the lorcaserin Phase 3 pivotal program and its NDA submission; Arena's financial position; plans for partnering discussions for lorcaserin and earlier-stage drug candidates; the safety and other potential of lorcaserin; and about Arena's strategy, potential, value, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to: the risk that the funding may not be completed when expected, or at all; Arena's ability to obtain additional funds; the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; results of clinical trials or preclinical studies may not be predictive of future results; the risk that lorcaserin may not be deemed adequately safe; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena's collaborators. Addition
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals Announces Public Offering of Common Stock
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
7. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
9. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
10. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... ... August 30, 2015 , ... ... medical devices for the treatment of prostate cancer, has announced the roll-out of ... at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is ... chiropractic field in the military. All too often VA hospitals treat patients with harmful ... to the VA program over a decade ago, the reality is that only 10% ...
(Date:8/29/2015)... ... 29, 2015 , ... People who have heart or lung ... asthma, are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with ... problems (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , ...
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College ... and the student experience as part of the EDUCAUSE - Next Generation Learning Challenges ... , This is the third Breakthrough Models Incubator hosted by EDUCAUSE and ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... Dec. 18 Many large companies depend,on successful ... portfolio. These alliances are developed to achieve common ... deals to tap into expertise of small biotech ... development expertise, and market,insight to the smaller companies., ...
... Art Mellor is one of,more than 400,000 people in ... (MS). It,s, a debilitating disease that causes,paralysis, blindness, incontinence ... that Mellor, the founder of the Accelerated,Cure Project for ... in raising the funds he needs to scratch "Develop ...
... over their daily activities and do challenging work they enjoy ... new study from The University of Texas at Austin published ... "The most important finding is that creative activity helps people ... with the Population Research Center at The University of Texas ...
... jeopardize further breakthroughs: report , , TUESDAY, Dec. 18 (HealthDay ... treatments for liver, kidney, head and neck and lung ... cancer care, the American Society of Clinical Oncology says ... while treatment is improving the lives of many cancer ...
... Cytopia,s first Phase II clinical trial, MELBOURNE, Australia, ... approval to proceed with a Phase II clinical,study assessing ... myeloma,patients. Patient enrolment will soon commence., This Phase ... further clinical,studies planned for the anti-cancer vascular-disrupting agent CYT997 ...
... Whether enjoying a meal at,home, at work or on ... don,t want to sacrifice great taste ... or convenience. ... leader in the frozen sandwich category has,found the solution. ... whole grains in every bite with seven delicious varieties ...
Cached Medicine News:Health News:Developing Excellence in Alliance 2Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 2Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 3Health News:Creative work has health advantages, Population Research Center study shows 2Health News:Cancer Care Advances in 2007 Offer Hope 2Health News:Cancer Care Advances in 2007 Offer Hope 3Health News:Cancer Care Advances in 2007 Offer Hope 4Health News:Cytopia Commences Phase II Cancer Drug Study 2Health News:Cytopia Commences Phase II Cancer Drug Study 3Health News:A Whole New Sandwich Debuts in the Freezer Aisle: LEAN POCKETS(R) Brand Introduces Latest Whole Grain Varieties 2Health News:A Whole New Sandwich Debuts in the Freezer Aisle: LEAN POCKETS(R) Brand Introduces Latest Whole Grain Varieties 3
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Tobramycin is a traditional antibiotic whose eye drop ... the treatment of potential infection or inflammation caused by ... China are able to produce tobramycin, among ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by Pharmacia & ... receptor agonist which effectively reduces intraocular pressure. As ... latanoprost (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ... it has completed the acquisition of leading OTC brands ... €200 million. The transaction is a clear demonstration of ... Company,s leading European distribution network spanning 36 countries.  ... C. Papa commented, "We are excited to complete ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... management in the biopharmaceutical industry will "redouble efforts at ... intellectual property theft, counterfeiting and piracy, along with real ... a resolution unanimously adopted by the trustees ... the group applauds the ongoing efforts by labor and ...
... Inc. (NASDAQ: IDIX ), announced today that Idenix ... Life Sciences Conference on September 21, 2011 at 2:00 p.m. ... The live and archived webcast of the company ... Idenix Investor Center at www.idenix.com . Please log in ...
Cached Medicine Technology:PILMA Vows to 'Redouble' Support for Increased Protections Against Intellectual Property Theft 2
... Gentian violet ink stands ... Millimeter scale ruler printed ... for quick measuring. Flexible, ... both inch and metric ...
Freer elevator, double end, 7 1/4", S/B....
Stainless steel dull finish....
The Ultima 2000 SE is flexible in meeting the needs of both office and operating room use. It is the answer for the clinical practice with a wide range of ophthalmic demands looking for minimal risk ...
Medicine Products: